PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 23137907-2 2013 It is well known that in aqueous suspensions, tetrabutylammonium (TBA) cations intercalate CNP"s layered structure, producing exfoliated platelets. Tetrabutylammonium bromide 46-64 2',3'-cyclic nucleotide 3' phosphodiesterase Homo sapiens 91-94 23557586-1 2013 The reaction of the multisite coordination ligand (LH4) with CoX2 nH2O in the presence of tetrabutylammonium hydroxide affords a series of homometallic dinuclear mixed-valence complexes, [Co(III)Co(II)(LH2)2(X)(H2O)](H2O)m (1, X = Cl and m = 4; 2, X = Br and m = 4; 3, X = NO3 and m = 3). Tetrabutylammonium bromide 90-118 mitochondrially encoded cytochrome c oxidase II Homo sapiens 61-65 23137907-2 2013 It is well known that in aqueous suspensions, tetrabutylammonium (TBA) cations intercalate CNP"s layered structure, producing exfoliated platelets. Tetrabutylammonium bromide 66-69 2',3'-cyclic nucleotide 3' phosphodiesterase Homo sapiens 91-94 23137907-4 2013 However, TBA leads to complete exfoliation of CNP (>95%) in suspensions prepared with TBA:CNP ratios greater than 1:1. Tetrabutylammonium bromide 9-12 2',3'-cyclic nucleotide 3' phosphodiesterase Homo sapiens 46-49 23137907-4 2013 However, TBA leads to complete exfoliation of CNP (>95%) in suspensions prepared with TBA:CNP ratios greater than 1:1. Tetrabutylammonium bromide 9-12 2',3'-cyclic nucleotide 3' phosphodiesterase Homo sapiens 93-96 23025526-1 2013 BACKGROUND: Thyrotropin receptor (TSHR) antibodies that stimulate the thyroid (TSAb) cause Graves" hyperthyroidism and TSHR antibodies which block thyrotropin action (TBAb) are occasionally responsible for hypothyroidism. Tetrabutylammonium bromide 167-171 thyroid stimulating hormone receptor Homo sapiens 12-32 23025526-1 2013 BACKGROUND: Thyrotropin receptor (TSHR) antibodies that stimulate the thyroid (TSAb) cause Graves" hyperthyroidism and TSHR antibodies which block thyrotropin action (TBAb) are occasionally responsible for hypothyroidism. Tetrabutylammonium bromide 167-171 thyroid stimulating hormone receptor Homo sapiens 119-123 23025526-6 2013 Finally, perhaps most important, as illustrated by dilution analyses of patients" sera in vitro, TSHR antibody concentrations and affinities play a critical role in switching TSAb and TBAb functional activities in vivo. Tetrabutylammonium bromide 184-188 thyroid stimulating hormone receptor Homo sapiens 97-101 17940192-6 2008 After replacement of Phe483 or Trp147 by cysteine or serine, high-affinity binding of TBuA leads to inhibition of MPP or TEA uptake, whereas it has no effect on cation uptake by wild-type rOCT1. Tetrabutylammonium bromide 86-90 solute carrier family 22 member 1 Rattus norvegicus 188-193 22852135-1 2012 A synthesis of enantiopure 19-nor-Vitamin D(3) and its C-2 substituted cyclic phosphate analogs is achieved via in situ trapping of an alpha-sulfonyl anion with a CD-ring allyl chloride and 1,2-eliminative desulfonylation exploiting the basic properties of TBAF. Tetrabutylammonium bromide 257-261 complement C2 Homo sapiens 55-58 20329720-1 2010 It is presently shown that long chain (C14, C16, and C18) alkanoic (saturated fatty) acids can form magnetically oriented hexagonal phases in aqueous concentrated solutions in mixtures with tetrabutylammonium (TBAOH) as the counterion. Tetrabutylammonium bromide 190-208 Bardet-Biedl syndrome 9 Homo sapiens 53-56 19552467-1 2009 Multisubstituted piperidines containing a trimethylsilylmethyl group at C-2 can be opened regioselectively with TBAF and cyanogen bromide. Tetrabutylammonium bromide 112-116 complement C2 Homo sapiens 72-75 19007306-5 2009 Additional experiments using AChE inhibitors (amphiphilic procaine hydrochloride, hydrophobic tetrabutylammonium bromide) in the absence or presence of detergent further illustrate the detergent-enzyme-solvent interactions. Tetrabutylammonium bromide 94-120 acetylcholinesterase (Cartwright blood group) Homo sapiens 29-33 18567714-7 2008 Radioimmunoassay showed that the release of substance P (SP) and CGRP after OLDA treatment was higher in WT than in TRPV1(-/-) hearts, which was blocked by chelerythrine or TBA. Tetrabutylammonium bromide 173-176 tachykinin 1 Mus musculus 44-55 18567714-7 2008 Radioimmunoassay showed that the release of substance P (SP) and CGRP after OLDA treatment was higher in WT than in TRPV1(-/-) hearts, which was blocked by chelerythrine or TBA. Tetrabutylammonium bromide 173-176 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 65-69 18567714-7 2008 Radioimmunoassay showed that the release of substance P (SP) and CGRP after OLDA treatment was higher in WT than in TRPV1(-/-) hearts, which was blocked by chelerythrine or TBA. Tetrabutylammonium bromide 173-176 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 116-121 21574649-2 2011 These dioxetanes underwent TBAF (tetrabutylammonium fluoride)-induced decomposition accompanied by the emission of light in DMSO and in acetonitrile at 25 C. For all three pairs of rotamers, the chemiluminescence efficiency Phi(CL) for anti-5 was 8-19 times higher than that for syn-5, and the rate of CTID (charge-transfer-induced decomposition) for anti-5 was faster than that for syn-5. Tetrabutylammonium bromide 27-31 syntrophin gamma 2 Homo sapiens 280-285 21574649-2 2011 These dioxetanes underwent TBAF (tetrabutylammonium fluoride)-induced decomposition accompanied by the emission of light in DMSO and in acetonitrile at 25 C. For all three pairs of rotamers, the chemiluminescence efficiency Phi(CL) for anti-5 was 8-19 times higher than that for syn-5, and the rate of CTID (charge-transfer-induced decomposition) for anti-5 was faster than that for syn-5. Tetrabutylammonium bromide 27-31 syntrophin gamma 2 Homo sapiens 384-389 21574649-2 2011 These dioxetanes underwent TBAF (tetrabutylammonium fluoride)-induced decomposition accompanied by the emission of light in DMSO and in acetonitrile at 25 C. For all three pairs of rotamers, the chemiluminescence efficiency Phi(CL) for anti-5 was 8-19 times higher than that for syn-5, and the rate of CTID (charge-transfer-induced decomposition) for anti-5 was faster than that for syn-5. Tetrabutylammonium bromide 33-60 syntrophin gamma 2 Homo sapiens 280-285 21574649-2 2011 These dioxetanes underwent TBAF (tetrabutylammonium fluoride)-induced decomposition accompanied by the emission of light in DMSO and in acetonitrile at 25 C. For all three pairs of rotamers, the chemiluminescence efficiency Phi(CL) for anti-5 was 8-19 times higher than that for syn-5, and the rate of CTID (charge-transfer-induced decomposition) for anti-5 was faster than that for syn-5. Tetrabutylammonium bromide 33-60 syntrophin gamma 2 Homo sapiens 384-389 21515058-6 2011 The efficient (11)C-labeling of ibuprofen for chiral separation via the TBAF-promoted alpha-[(11)C]methylation was achieved by using DMSO rather than THF as the reaction solvent. Tetrabutylammonium bromide 72-76 thin fur Mus musculus 150-153 18955595-4 2008 We found that all four QAs used, tetraethylammonium (TEA), tetrapropylammonium (TPrA), tetrabutylammonium, and tetrapentylammonium, block the TRPV1 channel from the intracellular face of the channel in a voltage-dependent manner, and that block by these molecules occurs with different kinetics, with the bigger molecules becoming slower blockers. Tetrabutylammonium bromide 87-105 transient receptor potential cation channel subfamily V member 1 Homo sapiens 142-147 17369424-0 2007 On the mechanism of TBA block of the TRPV1 channel. Tetrabutylammonium bromide 20-23 transient receptor potential cation channel subfamily V member 1 Homo sapiens 37-42 17616146-0 2007 Reusable Cu2O/PPh3/TBAB system for the cross-couplings of aryl halides and heteroaryl halides with terminal alkynes. Tetrabutylammonium bromide 19-23 caveolin 1 Homo sapiens 14-18 17616146-1 2007 An efficient and reusable Cu2O/PPh3/TBAB (n-Bu4NBr) system for the cross-coupling reactions of aryl and heteroaryl halides with terminal alkynes has been developed. Tetrabutylammonium bromide 36-40 caveolin 1 Homo sapiens 31-35 17616146-4 2007 Noteworthy is that the Cu2O/PPh3/TBAB system can be recovered and reused several times without loss of any activities. Tetrabutylammonium bromide 33-37 caveolin 1 Homo sapiens 28-32 17369424-8 2007 We propose an allosteric model for TRPV1 activation and block by TBA, which explains our experimental data. Tetrabutylammonium bromide 65-68 transient receptor potential cation channel subfamily V member 1 Homo sapiens 35-40 17179194-2 2007 Here we compare serum concentration, affinity to the TSH-R, and binding sites on the TSH-R of stimulating (TSAb) and blocking (TBAb) TRAbs. Tetrabutylammonium bromide 127-131 thyroid stimulating hormone receptor Homo sapiens 85-90 17179194-10 2007 Purified and labeled TSAb and TBAb showed a very similar binding pattern to the TSH-R in displacement studies with unlabeled TSAb/TBAb or unpurified patients sera, indicating binding sites on the TSH-R in close proximity to each other. Tetrabutylammonium bromide 30-34 thyroid stimulating hormone receptor Homo sapiens 80-85 17179194-10 2007 Purified and labeled TSAb and TBAb showed a very similar binding pattern to the TSH-R in displacement studies with unlabeled TSAb/TBAb or unpurified patients sera, indicating binding sites on the TSH-R in close proximity to each other. Tetrabutylammonium bromide 30-34 thyroid stimulating hormone receptor Homo sapiens 196-201 17179194-10 2007 Purified and labeled TSAb and TBAb showed a very similar binding pattern to the TSH-R in displacement studies with unlabeled TSAb/TBAb or unpurified patients sera, indicating binding sites on the TSH-R in close proximity to each other. Tetrabutylammonium bromide 130-134 thyroid stimulating hormone receptor Homo sapiens 80-85 17030371-6 2006 In additional studies, VIP at 1x10(-10)M decreased CVR by -22+/-1% in the absence (control) and by only -10+/-2% in the presence of the nonselective K(+) channel blocker tetrabutylammonium (3x10(-4)M; P<0.05 vs. control). Tetrabutylammonium bromide 170-188 vasoactive intestinal peptide Rattus norvegicus 23-26 17028000-3 2006 The chromatographic conditions for separation of the dye-based black gel pen inks were optimized and the dye components in inks were satisfactorily separated by using 40 mmol/L tetrabutylammonium bromide as ion-pairing reagent. Tetrabutylammonium bromide 177-203 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 73-76 16920127-2 2006 In this procedure, long-chain fatty acids (C(14), C(16) and C(18)) were converted into their ion-pair complexes with tetrabutylammonium hydrogen sulfate and then extracted by organic solvent (1-octanol) impregnated in the hollow fiber. Tetrabutylammonium bromide 117-152 Bardet-Biedl syndrome 9 Homo sapiens 60-65 16087335-1 2005 An efficient, high yield and one-pot synthesis of phenyl cyclopropyl methanones by reaction of different aryl alcohols with 4"-fluoro-4-chloro-butyrophenone in THF/DMF in the presence of NaH/TBAB is reported. Tetrabutylammonium bromide 191-195 thin fur Mus musculus 160-163 16448136-4 2006 NMR spectra (1D and 2D) of the channel in CDCl(3) showed significant variation in the absence and presence of stoichiometric tetrabutylammonium chloride (Bu(4)NCl). Tetrabutylammonium bromide 125-152 nucleolin Homo sapiens 159-162 16388664-1 2006 [reaction: see text] PdCl2(PPh3)2 combined with TBAF under solvent-free conditions provided general and fast Sonogashira cross-coupling reactions of aryl halides with terminal alkynes. Tetrabutylammonium bromide 48-52 phosducin like 2 Homo sapiens 21-26 16388664-1 2006 [reaction: see text] PdCl2(PPh3)2 combined with TBAF under solvent-free conditions provided general and fast Sonogashira cross-coupling reactions of aryl halides with terminal alkynes. Tetrabutylammonium bromide 48-52 caveolin 1 Homo sapiens 27-31 16388664-3 2006 In the presence of 3 mol % of PdCl2(PPh3)2 and 3 equiv of TBAF, a number of ArX species (X = I, Br, Cl) were coupled with alkynes to afford the corresponding products in moderate to excellent yields under copper-, amine-, and solvent-free conditions. Tetrabutylammonium bromide 58-62 aristaless related homeobox Homo sapiens 76-79 16961344-1 2006 The diffusion reaction of TBA2Cu(II)Cl4 (TBA = tetrabutylammonium) and a N-containing organic donor, BP-TTF [=bis(pyrazino)tetrathiafulvalene], yielded a 3-D supramolecular Cu complex, [CuCl2(BP-TTF)] (1). Tetrabutylammonium bromide 47-65 ras homolog family member H Homo sapiens 104-107 16961344-1 2006 The diffusion reaction of TBA2Cu(II)Cl4 (TBA = tetrabutylammonium) and a N-containing organic donor, BP-TTF [=bis(pyrazino)tetrathiafulvalene], yielded a 3-D supramolecular Cu complex, [CuCl2(BP-TTF)] (1). Tetrabutylammonium bromide 47-65 ras homolog family member H Homo sapiens 195-198 16584516-1 2006 BACKGROUND: TSH receptor antibodies (TBII) in Graves" disease (GD) may be TSH receptor stimulating (TSAb) and blocking (TBAb) antibodies. Tetrabutylammonium bromide 120-124 thyroid stimulating hormone receptor Homo sapiens 12-24 16584516-1 2006 BACKGROUND: TSH receptor antibodies (TBII) in Graves" disease (GD) may be TSH receptor stimulating (TSAb) and blocking (TBAb) antibodies. Tetrabutylammonium bromide 120-124 thyroid stimulating hormone receptor Homo sapiens 74-86 16232366-2 2005 The present study was performed to elucidate the relationship between CD134/CD137 molecules and stimulating (TSAb) or blocking (TBAb) antibodies to the TSH-receptor in Graves" disease. Tetrabutylammonium bromide 128-132 TNF receptor superfamily member 4 Homo sapiens 70-75 15961385-7 2005 We found that dimethylamine, triethylamine, tetraethylammonium, tetrabutylammonium, tetrapropylammonium, and tetrapentylammonium were permeable through the PC2 channel. Tetrabutylammonium bromide 64-82 polycystin 2, transient receptor potential cation channel Homo sapiens 156-159 16232366-2 2005 The present study was performed to elucidate the relationship between CD134/CD137 molecules and stimulating (TSAb) or blocking (TBAb) antibodies to the TSH-receptor in Graves" disease. Tetrabutylammonium bromide 128-132 TNF receptor superfamily member 9 Homo sapiens 76-81 16232366-2 2005 The present study was performed to elucidate the relationship between CD134/CD137 molecules and stimulating (TSAb) or blocking (TBAb) antibodies to the TSH-receptor in Graves" disease. Tetrabutylammonium bromide 128-132 thyroid stimulating hormone receptor Homo sapiens 152-164 16220002-1 2005 The present study was performed to elucidate the relationship between CTLA-4/CD28 molecules and stimulating (TSAb) and blocking (TBAb) antibodies to the TSH-receptor (TSH-R) in Graves" disease. Tetrabutylammonium bromide 129-133 cytotoxic T-lymphocyte associated protein 4 Homo sapiens 70-76 16220002-1 2005 The present study was performed to elucidate the relationship between CTLA-4/CD28 molecules and stimulating (TSAb) and blocking (TBAb) antibodies to the TSH-receptor (TSH-R) in Graves" disease. Tetrabutylammonium bromide 129-133 CD28 molecule Homo sapiens 77-81 16220002-1 2005 The present study was performed to elucidate the relationship between CTLA-4/CD28 molecules and stimulating (TSAb) and blocking (TBAb) antibodies to the TSH-receptor (TSH-R) in Graves" disease. Tetrabutylammonium bromide 129-133 thyroid stimulating hormone receptor Homo sapiens 153-165 16220002-1 2005 The present study was performed to elucidate the relationship between CTLA-4/CD28 molecules and stimulating (TSAb) and blocking (TBAb) antibodies to the TSH-receptor (TSH-R) in Graves" disease. Tetrabutylammonium bromide 129-133 thyroid stimulating hormone receptor Homo sapiens 167-172 16220002-5 2005 Detection of TSAb and TBAb to the TSH-R using JPO9 CHO cells in unfractionated serum was measured by a highly sensitive commercial radioimmunoassay. Tetrabutylammonium bromide 22-26 thyrotropin receptor Cricetulus griseus 34-39 16220002-9 2005 In patients with untreated GD there was a statistically significant positive correlation between the expression of CTLA-4 on the surface of peripheral blood T cells and the index of TSAb antibodies (R = 0.54, p < 0.001) as well as a negative correlation with TBAb antibody titer (R = -0.58, p < 0.001). Tetrabutylammonium bromide 262-266 cytotoxic T-lymphocyte associated protein 4 Homo sapiens 115-121 12482826-2 2002 METHODS AND RESULTS: Depolarization by the cation channel gramicidin (100 nmol/L) or tetrabutylammonium chloride (1 mmol/L) induced O2- release from HUVECs (n=4), which was decreased by superoxide dismutase (SOD, 500 U/mL). Tetrabutylammonium bromide 85-112 superoxide dismutase 1 Homo sapiens 186-206 15074993-5 2004 Measurements of D for solutions containing 0.5 mol L(-1) tetrabutylammonium perchlorate (TBAP) at 25 degrees C and ambient pressure are inversely proportional to the viscosities eta of the pure solvents as expected from the Stokes-Einstein relation, despite the fact that increasing [TBAP] results in increased eta. Tetrabutylammonium bromide 55-87 endothelin receptor type A Homo sapiens 178-181 15074993-5 2004 Measurements of D for solutions containing 0.5 mol L(-1) tetrabutylammonium perchlorate (TBAP) at 25 degrees C and ambient pressure are inversely proportional to the viscosities eta of the pure solvents as expected from the Stokes-Einstein relation, despite the fact that increasing [TBAP] results in increased eta. Tetrabutylammonium bromide 89-93 endothelin receptor type A Homo sapiens 178-181 15074993-5 2004 Measurements of D for solutions containing 0.5 mol L(-1) tetrabutylammonium perchlorate (TBAP) at 25 degrees C and ambient pressure are inversely proportional to the viscosities eta of the pure solvents as expected from the Stokes-Einstein relation, despite the fact that increasing [TBAP] results in increased eta. Tetrabutylammonium bromide 89-93 endothelin receptor type A Homo sapiens 311-314 15074993-6 2004 The activation volume Delta V(diff)(++) for diffusion of DmFc(+/0) ranges from 7 to 17 cm(3) mol(-1) and generally increases with increasing eta and thus with increasing [TBAP]. Tetrabutylammonium bromide 171-175 endothelin receptor type A Homo sapiens 141-144 15012609-1 2004 OBJECTIVE: We describe an infant with surprisingly severe neonatal hypothyroidism due to transplacental passage of thyrotrophin receptor (TSH-R)-blocking antibodies (TBAb). Tetrabutylammonium bromide 166-170 thyroid stimulating hormone receptor Homo sapiens 89-136 15012609-1 2004 OBJECTIVE: We describe an infant with surprisingly severe neonatal hypothyroidism due to transplacental passage of thyrotrophin receptor (TSH-R)-blocking antibodies (TBAb). Tetrabutylammonium bromide 166-170 thyroid stimulating hormone receptor Homo sapiens 138-143 15012609-2 2004 DESIGN AND METHODS: TBAb were detected using a cell line which stably expresses the human TSH-R and a cAMP-responsive luciferase reporter by their ability to inhibit TSH-stimulated luciferase expression. Tetrabutylammonium bromide 20-24 thyroid stimulating hormone receptor Homo sapiens 90-95 15504312-2 2004 The present study was performed to elucidate the relationship between CTLA-4/CD28 molecules and stimulating (TSAb) or blocking (TBAb) antibodies to the TSH-receptor in Graves" disease. Tetrabutylammonium bromide 128-132 cytotoxic T-lymphocyte associated protein 4 Homo sapiens 70-76 15504312-2 2004 The present study was performed to elucidate the relationship between CTLA-4/CD28 molecules and stimulating (TSAb) or blocking (TBAb) antibodies to the TSH-receptor in Graves" disease. Tetrabutylammonium bromide 128-132 CD28 molecule Homo sapiens 77-81 15504312-2 2004 The present study was performed to elucidate the relationship between CTLA-4/CD28 molecules and stimulating (TSAb) or blocking (TBAb) antibodies to the TSH-receptor in Graves" disease. Tetrabutylammonium bromide 128-132 thyroid stimulating hormone receptor Homo sapiens 152-164 14573752-2 2003 Tetrabutylammonium (TBuA) and corticosterone were identified as nontransported inhibitors that bind to the substrate binding site of rOCT2. Tetrabutylammonium bromide 0-18 solute carrier family 22 member 2 Rattus norvegicus 133-138 14573752-2 2003 Tetrabutylammonium (TBuA) and corticosterone were identified as nontransported inhibitors that bind to the substrate binding site of rOCT2. Tetrabutylammonium bromide 20-24 solute carrier family 22 member 2 Rattus norvegicus 133-138 12482826-2 2002 METHODS AND RESULTS: Depolarization by the cation channel gramicidin (100 nmol/L) or tetrabutylammonium chloride (1 mmol/L) induced O2- release from HUVECs (n=4), which was decreased by superoxide dismutase (SOD, 500 U/mL). Tetrabutylammonium bromide 85-112 superoxide dismutase 1 Homo sapiens 208-211 12201788-2 2002 Under the catalysis of 1 mol % Pd(PPh3)4, the reaction of 4,4-disubstituted 2,3-allenamides and organic iodides in toluene afforded iminolactones stereospecifically in >90% yields using K2CO3 (2 equiv)-5 mol % TBAB as the base. Tetrabutylammonium bromide 213-217 caveolin 1 Homo sapiens 34-38 11547349-12 2001 Introducing 100 mm inhibitor into the DF reduced J(HCO3) to approximately 20 pmole cm(-2) sec(-1) for tetramethylammonium (TMA(+)), approximately 24 for TEA(+), approximately 10 for tetrapropylammonium (TPA(+)), and virtually zero for tetrabutylammonium (TBA(+)). Tetrabutylammonium bromide 235-253 secretory blood group 1, pseudogene Homo sapiens 90-96 11850483-3 2002 METHODS: No-carrier-added (18)F-FECh was synthesized by 2-step reactions: First, tetrabutylammonium (TBA) (18)F-fluoride was reacted with 1,2-bis(tosyloxy)ethane to yield 2-(18)F-fluoroethyl tosylate; and second, 2-(18)F-fluoroethyl tosylate was reacted with N,N-dimethylethanolamine to yield (18)F-FECh, which was then purified by chromatography. Tetrabutylammonium bromide 81-99 ferrochelatase Homo sapiens 32-36 11850483-3 2002 METHODS: No-carrier-added (18)F-FECh was synthesized by 2-step reactions: First, tetrabutylammonium (TBA) (18)F-fluoride was reacted with 1,2-bis(tosyloxy)ethane to yield 2-(18)F-fluoroethyl tosylate; and second, 2-(18)F-fluoroethyl tosylate was reacted with N,N-dimethylethanolamine to yield (18)F-FECh, which was then purified by chromatography. Tetrabutylammonium bromide 81-99 ferrochelatase Homo sapiens 299-303 11850483-3 2002 METHODS: No-carrier-added (18)F-FECh was synthesized by 2-step reactions: First, tetrabutylammonium (TBA) (18)F-fluoride was reacted with 1,2-bis(tosyloxy)ethane to yield 2-(18)F-fluoroethyl tosylate; and second, 2-(18)F-fluoroethyl tosylate was reacted with N,N-dimethylethanolamine to yield (18)F-FECh, which was then purified by chromatography. Tetrabutylammonium bromide 101-104 ferrochelatase Homo sapiens 32-36 11850483-3 2002 METHODS: No-carrier-added (18)F-FECh was synthesized by 2-step reactions: First, tetrabutylammonium (TBA) (18)F-fluoride was reacted with 1,2-bis(tosyloxy)ethane to yield 2-(18)F-fluoroethyl tosylate; and second, 2-(18)F-fluoroethyl tosylate was reacted with N,N-dimethylethanolamine to yield (18)F-FECh, which was then purified by chromatography. Tetrabutylammonium bromide 101-104 ferrochelatase Homo sapiens 299-303 12060594-4 2002 n-Tetraalkylammonium compounds showed similar affinities for the two homologs, with IC50 values for inhibition of OCT1- and OCT2-mediated [3H]TEA transport, respectively, of 4,538 and 1,395 microM for tetramethylammonium, 88.5 and 3.9 microM for tetrapropylammonium, 13.9 and 5.3 microM for tetrabutylammonium, and 8.8 and 7.6 microM for tetrapentylammonium. Tetrabutylammonium bromide 291-309 solute carrier family 22 member 1 Oryctolagus cuniculus 114-118 12060594-4 2002 n-Tetraalkylammonium compounds showed similar affinities for the two homologs, with IC50 values for inhibition of OCT1- and OCT2-mediated [3H]TEA transport, respectively, of 4,538 and 1,395 microM for tetramethylammonium, 88.5 and 3.9 microM for tetrapropylammonium, 13.9 and 5.3 microM for tetrabutylammonium, and 8.8 and 7.6 microM for tetrapentylammonium. Tetrabutylammonium bromide 291-309 solute carrier family 22 member 2 Oryctolagus cuniculus 124-128 11522609-10 2001 The indomethacin/L-NOARG-resistant relaxation induced by bradykinin was completely inhibited by 3 mM tetrabutylammonium (non-specific Ca(2+)-activated K(+) channel blocker), while that induced by substance P was not inhibited by 3 mM tetrabutylammonium or 1 mM 4-aminopyridine (voltage-dependent K(+) channels blocker) alone, but completely inhibited by their combination. Tetrabutylammonium bromide 101-119 kininogen 1 Homo sapiens 57-67 11522609-10 2001 The indomethacin/L-NOARG-resistant relaxation induced by bradykinin was completely inhibited by 3 mM tetrabutylammonium (non-specific Ca(2+)-activated K(+) channel blocker), while that induced by substance P was not inhibited by 3 mM tetrabutylammonium or 1 mM 4-aminopyridine (voltage-dependent K(+) channels blocker) alone, but completely inhibited by their combination. Tetrabutylammonium bromide 101-119 tachykinin precursor 1 Homo sapiens 196-207 11522609-10 2001 The indomethacin/L-NOARG-resistant relaxation induced by bradykinin was completely inhibited by 3 mM tetrabutylammonium (non-specific Ca(2+)-activated K(+) channel blocker), while that induced by substance P was not inhibited by 3 mM tetrabutylammonium or 1 mM 4-aminopyridine (voltage-dependent K(+) channels blocker) alone, but completely inhibited by their combination. Tetrabutylammonium bromide 234-252 kininogen 1 Homo sapiens 57-67 11072849-2 2000 An analogous sequence with the corresponding O-acetylated sucrose derivative and tetrabutylammonium fluoride as desilylating agent resulted in a lower yield of the C-1" hydroxy derivative. Tetrabutylammonium bromide 81-108 heterogeneous nuclear ribonucleoprotein C Homo sapiens 164-167 11589506-7 2001 Tetrabutylammonium also inhibited the acetylcholine- but not nitroprusside-induced increase of tissue content of cyclic GMP in the aortic rings. Tetrabutylammonium bromide 0-18 5'-nucleotidase, cytosolic II Homo sapiens 120-123 11379689-8 2001 The relaxant responses to acetylcholine and bradykinin were attenuated by L-NAME or TBA alone and were abolished by combined inhibition in rings pretreated with ibuprofen. Tetrabutylammonium bromide 84-87 kininogen 1 Canis lupus familiaris 44-54 11316266-0 2001 Tetrabutylammonium: a selective blocker of the somatostatin-activated hyperpolarizing current in mouse AtT-20 corticotrophs. Tetrabutylammonium bromide 0-18 somatostatin Mus musculus 47-59 11126298-5 2000 Cleavage of the oxazolidines from the resin support was achieved with TBAF to give the individual members (2R,4R,5R)-5Aaa-Cdd and (2S,4S,5S)-6Aaa-Cdd in good to excellent yields (51-99%) based on mass recovery. Tetrabutylammonium bromide 70-74 natriuretic peptide A Homo sapiens 122-125 11126298-5 2000 Cleavage of the oxazolidines from the resin support was achieved with TBAF to give the individual members (2R,4R,5R)-5Aaa-Cdd and (2S,4S,5S)-6Aaa-Cdd in good to excellent yields (51-99%) based on mass recovery. Tetrabutylammonium bromide 70-74 natriuretic peptide A Homo sapiens 146-149 9689028-1 1998 We studied block of the internal pore of the ROMK1 inward-rectifier K+ channel by Mg2+ and five quaternary ammoniums (tetramethylammonium, tetraethylammonium, tetrapropylammonium, tetrabutylammonium, and tetrapentylammonium). Tetrabutylammonium bromide 180-198 potassium inwardly rectifying channel subfamily J member 1 Homo sapiens 45-50 10688634-7 2000 For the mouse homolog mOCT1, apparent K(i) values ranged from 7 microM for tetrabutylammonium to 2000 microM for tetramethylammonium. Tetrabutylammonium bromide 75-93 solute carrier family 22 (organic cation transporter), member 1 Mus musculus 22-27 10218957-6 1999 The endothelium-dependent component of PTHrP and PTH-induced aortic relaxations were unaffected by pretreatment with either L-NNA or indomethacin but were abolished by pretreatment with tetrabutyl ammonium. Tetrabutylammonium bromide 186-205 parathyroid hormone-like peptide Mus musculus 39-44 10218957-6 1999 The endothelium-dependent component of PTHrP and PTH-induced aortic relaxations were unaffected by pretreatment with either L-NNA or indomethacin but were abolished by pretreatment with tetrabutyl ammonium. Tetrabutylammonium bromide 186-205 parathyroid hormone Mus musculus 39-42 10790152-5 2000 Hence, cell depolarization with 70 mM extracellular K+ or the inhibition of non-selective cation channels (NSCCs) and KCa channels by 10 microM Loe 908 and 10 mM tetrabutylammonium prevented histamine-evoked Ca2+ oscillations. Tetrabutylammonium bromide 162-180 casein kappa Homo sapiens 118-121 18967614-0 1999 Effect of tetrabutylammonium chloride as eluent modifier on the retention and enantioselectivity of d,l-dansyl amino acids using immobilized human serum albumin. Tetrabutylammonium bromide 10-37 albumin Homo sapiens 147-160 10027858-9 1999 trans-Stimulation studies revealed that TEA, tetrapropylammonium, tetrabutylammonium, as well as tributylmethylammonium trans-stimulated TEA uptake mediated by hOCT1. Tetrabutylammonium bromide 66-84 solute carrier family 22 member 1 Homo sapiens 160-165 9222556-9 1997 The VIP-induced decreases in the [Ca2+]i and force were attenuated by K+ channel blockers such as tetrabutylammonium (TBA: non-selective K+ channel blocker), charybdotoxin (large conductance Ca(2+)-activated K+ channel blocker), and 4-aminopyridine (4-AP: voltage-dependent K+ channel blocker). Tetrabutylammonium bromide 98-116 vasoactive intestinal peptide Homo sapiens 4-7 11671822-1 1997 The "ligandless" palladium acetate-catalyzed Suzuki cross-coupling reaction of ArX with aryl- and vinylboronic acids in water without organic cosolvent in the presence of tetrabutylammonium bromide is reported. Tetrabutylammonium bromide 171-197 aristaless related homeobox Homo sapiens 79-82 34282920-1 2021 The present work reports highly efficient flexible and reabsorption-free scintillators based on two zero-dimensional (0D) organic copper halides (TBA)CuX2 (TBA = tetrabutylammonium cation; X = Cl, Br). Tetrabutylammonium bromide 162-180 cut like homeobox 2 Homo sapiens 150-154 9208131-15 1997 The indomethacin plus L-NAME resistant component of the relaxation to BK was significantly attenuated by the K+ channel blocker tetrabutylammonium (TBA, 1 mM). Tetrabutylammonium bromide 128-146 kininogen 1 Homo sapiens 70-72 9208131-15 1997 The indomethacin plus L-NAME resistant component of the relaxation to BK was significantly attenuated by the K+ channel blocker tetrabutylammonium (TBA, 1 mM). Tetrabutylammonium bromide 148-151 kininogen 1 Homo sapiens 70-72 8975535-0 1996 [Competitive binding of tetrabutylammonium and cetylpyridinium cations on C18 surfaces]. Tetrabutylammonium bromide 24-42 Bardet-Biedl syndrome 9 Homo sapiens 74-77 8784921-1 1996 A method for preparing various forms of acetylcholinesterase (AChE) from human erythrocyte has been established and they have been characterized in terms of kinetic parameters such as K(m), rate constant (k), turnover number (kcat), specificity constant (ksp), Vmax, half-life (t1/2), IC50 and Ki for tetrabutylammonium hydroxide, procaine and physostigmine in the present study. Tetrabutylammonium bromide 301-329 acetylcholinesterase (Cartwright blood group) Homo sapiens 40-60 8784921-1 1996 A method for preparing various forms of acetylcholinesterase (AChE) from human erythrocyte has been established and they have been characterized in terms of kinetic parameters such as K(m), rate constant (k), turnover number (kcat), specificity constant (ksp), Vmax, half-life (t1/2), IC50 and Ki for tetrabutylammonium hydroxide, procaine and physostigmine in the present study. Tetrabutylammonium bromide 301-329 acetylcholinesterase (Cartwright blood group) Homo sapiens 62-66 7478918-3 1995 In outside-out patches of Kv 3.1, the relative potencies were TEA > tetrapropylammonium (TPA) > tetrabutylammonium (TBA). Tetrabutylammonium bromide 102-120 potassium voltage-gated channel subfamily C member 1 Homo sapiens 26-32 7478918-3 1995 In outside-out patches of Kv 3.1, the relative potencies were TEA > tetrapropylammonium (TPA) > tetrabutylammonium (TBA). Tetrabutylammonium bromide 122-125 potassium voltage-gated channel subfamily C member 1 Homo sapiens 26-32 7478918-4 1995 In contrast to Kv 3.1, the relative potencies in Kv 2.1 were TBA > TEA > TPA. Tetrabutylammonium bromide 61-64 potassium voltage-gated channel subfamily B member 1 Homo sapiens 49-55 7745024-5 1995 From these results, it is concluded that the TSHR in infant adipocytes is likely to be coupled to the adenylate cyclase system, and the lipolytic effect of TSH can be simulated by stimulatory TSHR autoantibodies or inhibited by TBab. Tetrabutylammonium bromide 228-232 thyroid stimulating hormone receptor Homo sapiens 45-49 7745024-5 1995 From these results, it is concluded that the TSHR in infant adipocytes is likely to be coupled to the adenylate cyclase system, and the lipolytic effect of TSH can be simulated by stimulatory TSHR autoantibodies or inhibited by TBab. Tetrabutylammonium bromide 228-232 thyroid stimulating hormone receptor Homo sapiens 192-196 7738833-9 1994 Inhibitors of Ca(2+)-activated K+ channels (K+Ca), such as apamin (1 microM) and tetrabutylammonium (TBA, 3 mM), strongly attenuated the EDHF-mediated bradykinin-induced relaxation, while glibenclamide (3 microM), an inhibitor of K+ATP channels, had no effect. Tetrabutylammonium bromide 81-99 kininogen 1 Bos taurus 151-161 7738833-9 1994 Inhibitors of Ca(2+)-activated K+ channels (K+Ca), such as apamin (1 microM) and tetrabutylammonium (TBA, 3 mM), strongly attenuated the EDHF-mediated bradykinin-induced relaxation, while glibenclamide (3 microM), an inhibitor of K+ATP channels, had no effect. Tetrabutylammonium bromide 101-104 kininogen 1 Bos taurus 151-161 7521457-5 1994 Bradykinin increased [Ca2+]i, and this action was antagonized by the B2 kinin receptor antagonist Hoe 140 and the K channel inhibitor tetrabutylammonium (TBA). Tetrabutylammonium bromide 134-152 kininogen 1 Bos taurus 0-10 7521457-5 1994 Bradykinin increased [Ca2+]i, and this action was antagonized by the B2 kinin receptor antagonist Hoe 140 and the K channel inhibitor tetrabutylammonium (TBA). Tetrabutylammonium bromide 154-157 kininogen 1 Bos taurus 0-10 7521457-8 1994 The results indicate that the bradykinin response is mediated by biosynthesis of EDRF, which is sensitive to L-NNA, and of EDHF, which is sensitive to TBA. Tetrabutylammonium bromide 151-154 kininogen 1 Bos taurus 30-40 1459042-0 1992 The effect of tetrabutylammonium ion on chicken brain acetylcholinesterase activity in vitro. Tetrabutylammonium bromide 14-36 acetylcholinesterase (Cartwright blood group) Gallus gallus 54-74 1459042-1 1992 The effect of tetrabutylammonium ion on chicken brain acetylcholinesterase activity was investigated. Tetrabutylammonium bromide 14-36 acetylcholinesterase (Cartwright blood group) Gallus gallus 54-74 1459042-2 1992 Tetrabutylammonium ion (1-4mM) reversibly inhibited acetylcholinesterase activity of chicken brain (34-73%) in a concentration dependent manner, the IC50 being about 1.1mM. Tetrabutylammonium bromide 0-22 acetylcholinesterase (Cartwright blood group) Gallus gallus 52-72 2388254-3 1990 Bradykinin- and Ca2(+)-activated K+ currents were identified and shown to be blocked by the alkylammonium compound, tetrabutylammonium chloride and by the scorpion toxin, noxiustoxin, but not by apamin or tetraethylammonium chloride. Tetrabutylammonium bromide 116-143 kininogen 1 Bos taurus 0-10 7795392-2 1995 A fluorogenic reagent, DBPM easily reacted with D- or L-penicillamine to give each two kinds of strong fluorescent derivatives (D1-, D2-, L1- and L2-DBPM), which could be separated on a Pirkle-type chiral stationary phase using an eluent of 75% aqueous methanol solution containing 0.15 M CH3COONH4 and 0.05 M tetra-n-butylammonium bromide. Tetrabutylammonium bromide 310-339 immunoglobulin kappa variable 3-15 Homo sapiens 146-153 7956939-9 1994 Total T4 levels were also heterogeneous even before immunization, but 9 of 15 MBP-ECD-treated mice had levels below the normal range after immunization, and 7 of these also had TBII/TBAb activities. Tetrabutylammonium bromide 182-186 myelin basic protein Mus musculus 78-81 1501139-13 1992 In tissues contracted with high K+ or tetrabutylammonium (a non-selective K(+)-channel blocker), bradykinin inhibited the contractions in a concentration-dependent manner, whereas membrane hyperpolarization was not observed. Tetrabutylammonium bromide 38-56 kininogen 1 Homo sapiens 97-107 1759707-2 1991 The chelate is separated on C18-bonded silica packing by using an aqueous methanol mobile phase containing tetrabutylammonium bromide and is detected with 0.005 AU full-scale at 510 nm. Tetrabutylammonium bromide 107-133 Bardet-Biedl syndrome 9 Homo sapiens 28-31 2149290-8 1990 Tetrabutylammonium (TBA), a nonselective K+ channel blocker, or glibenclamide, a supposed adenosine 5"-triphosphate (ATP)-sensitive K+ channel blocker, abolished the reduction of [Ca2+]i caused by the three K+ channel openers and the relaxant effect of cromakalim, whereas they only slightly attenuated the relaxant effects of pinacidil and nicorandil. Tetrabutylammonium bromide 0-18 carbonic anhydrase 2 Canis lupus familiaris 180-183 2149290-8 1990 Tetrabutylammonium (TBA), a nonselective K+ channel blocker, or glibenclamide, a supposed adenosine 5"-triphosphate (ATP)-sensitive K+ channel blocker, abolished the reduction of [Ca2+]i caused by the three K+ channel openers and the relaxant effect of cromakalim, whereas they only slightly attenuated the relaxant effects of pinacidil and nicorandil. Tetrabutylammonium bromide 20-23 carbonic anhydrase 2 Canis lupus familiaris 180-183 34494839-6 2021 On the other hand, tetrabutylammonium iodide (TBAI) and butylamine (BA) clearly reduce the VIE for liquid water, which is attributed to the formation of an electric double layer (EDL) by segregated solutes at the gas-liquid interface. Tetrabutylammonium bromide 19-44 gastrin Homo sapiens 213-216 34494839-6 2021 On the other hand, tetrabutylammonium iodide (TBAI) and butylamine (BA) clearly reduce the VIE for liquid water, which is attributed to the formation of an electric double layer (EDL) by segregated solutes at the gas-liquid interface. Tetrabutylammonium bromide 46-50 gastrin Homo sapiens 213-216 34133113-4 2021 The turnover frequency (TOF) of the bifunctional polymer is more than four-fold that of the physical mixture of tetrabutylammonium bromide and porphyrin-Zn-incorporated polymer, implying the enhanced cooperation between Br- and porphyrin-Zn in the polymer network. Tetrabutylammonium bromide 112-138 chromosome 12 open reading frame 73 Homo sapiens 220-222 35471858-6 2022 Complexes 1-4 showed Co(III)-Co(II) redox responses near -0.2 V versus saturated calomel electrode (SCE) in dimethylformamide (DMF)-0.1 M tetrabutylammonium perchlorate (TBAP). Tetrabutylammonium bromide 138-168 mitochondrially encoded cytochrome c oxidase III Homo sapiens 21-28 35596807-6 2022 The results indicated that the TBAF(tert-butanol) complex plays the key role to increase the SN2 selectivity, whereas higher aggregates are not relevant. Tetrabutylammonium bromide 31-35 solute carrier family 38 member 5 Homo sapiens 93-96 35471858-6 2022 Complexes 1-4 showed Co(III)-Co(II) redox responses near -0.2 V versus saturated calomel electrode (SCE) in dimethylformamide (DMF)-0.1 M tetrabutylammonium perchlorate (TBAP). Tetrabutylammonium bromide 170-174 mitochondrially encoded cytochrome c oxidase III Homo sapiens 21-28 34028933-6 2021 Polymers P4 and P5 are stable in the absence of tetrabutylammonium fluoride (TBAF), while in the presence of TBAF, the molar masses of P4 and P5 gradually decrease with time together with the increase of the amount of formed 2,4-disubstitued gamma-butyrolactone. Tetrabutylammonium bromide 48-75 solute carrier family 10 member 4 Homo sapiens 9-18 7380913-7 1980 Investigations into the nature of the hydroxy acid metabolite of VP 16-213, carried out using paired-ion chromatography with tetrabutylammonium bromide and fluorescence detection, are described. Tetrabutylammonium bromide 125-151 host cell factor C1 Homo sapiens 65-70 5808832-1 1969 Medium-chain (C(6) and longer) fatty acids, as well as 12-hydroxystearic and long-chain fatty acids, can be quantitatively extracted into toluene and titrated in the toluene phase with tetrabutylammonium hydroxide. Tetrabutylammonium bromide 185-213 complement C6 Homo sapiens 14-42 2768373-2 1989 Ion-pair chromatography with tetrabutylammonium ion as the counter ion allowed for the complete resolution of all compounds at pH 7.5 on a reversed-phase (C18) column, thus permitting direct fluorescence detection without the use of post-column pH switching techniques. Tetrabutylammonium bromide 29-47 Bardet-Biedl syndrome 9 Homo sapiens 155-158 6098279-3 1984 A mixture of the ACTH fragments 1-4, 5-12, 13-24, 5-24, and 1-24 has been resolved on a Zorbax C8 column using methanol - 0,01 M tetrabutylammonium bromide (94:6) as mobile phase. Tetrabutylammonium bromide 129-155 proopiomelanocortin Homo sapiens 17-21 34028933-6 2021 Polymers P4 and P5 are stable in the absence of tetrabutylammonium fluoride (TBAF), while in the presence of TBAF, the molar masses of P4 and P5 gradually decrease with time together with the increase of the amount of formed 2,4-disubstitued gamma-butyrolactone. Tetrabutylammonium bromide 109-113 solute carrier family 10 member 4 Homo sapiens 135-144 33076095-1 2021 Preconcentration of Cd(II), Co(II), Cu(II), Ni(II), Pb(II), and Zn(II) in aqueous biphasic system tetrabutylammonium bromide (TBAB) - H2O - (NH4)2SO4 followed by ICP-OES determination is reported for the first time. Tetrabutylammonium bromide 98-124 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-34 32956424-8 2020 Here, we find that the aqueous TBAB+PEG-8 (1:4) solvent shows ~60% lower total energy consumption and higher CO2 removal when compared to those using the MEG solvent. Tetrabutylammonium bromide 31-35 IGF2 antisense RNA Homo sapiens 36-41 29136913-6 2018 When DPP1 was combined with Ag NPs and reacted with tetrabutylammonium fluoride or inorganic fluoride in aqueous samples, an obvious Raman enhancement was obtained at the excitation wavelength of 633nm. Tetrabutylammonium bromide 52-79 cathepsin C Homo sapiens 5-9 32846053-2 2020 The synthesis of the cnm5 U phosphoramidite building block starts with commercially available 5-methyluridine (m5 C), followed by bromination of the 5-methyl group to install the cyano moiety using TMSCN/TBAF. Tetrabutylammonium bromide 204-208 striated muscle enriched protein kinase Homo sapiens 21-25 32057247-1 2020 An efficient, solvent-free synthesis of 2-acylthieno[2,3-b]quinolines is reported from 2-halo-quinolinyl ketones through Cu-TEMPO catalyzed dehydrogenation, sp2-C-H functionalization using elemental sulfur as thiol surrogate (sulfur source) and tetrabutylammonium acetate as an ionic reaction medium. Tetrabutylammonium bromide 245-271 Sp2 transcription factor Homo sapiens 157-160 31573794-0 2019 Silk Fibroin Dissolution in Tetrabutylammonium Hydroxide Aqueous Solution. Tetrabutylammonium bromide 28-56 fibroin light chain Bombyx mori 5-12 31120467-2 2019 Surprisingly, the reaction of (gamma,beta)-diiodo-vinyl-phosphonate with TBAF [n-Bu4NF] led to the corresponding allenylphosphonate; in contrast, the use of CsF in a similar reaction led to novel gamma-diiodo-allenylphosphonate along with the corresponding non-halogenated allenylphosphonate. Tetrabutylammonium bromide 73-77 laminin subunit gamma 2 Homo sapiens 157-160 31207654-16 2019 The bridge assay is, however, also positive in the presence of TSHR blocking antibodies detected in a TBAb bioassay. Tetrabutylammonium bromide 102-106 thyroid stimulating hormone receptor Homo sapiens 63-67 30172109-1 2018 A catalytic and metal free sulfoxidation of O-2-(2-propylthiol)benzyl (OPTB) glycosides to O-2-(2-propylsulfinyl)benzyl (OPSB) glycosides has been developed by introducing NOBF4 as catalyst, oxygen as terminal oxidant and TBAB as additive. Tetrabutylammonium bromide 222-226 immunoglobulin kappa variable 1D-39 Homo sapiens 44-47 30172109-1 2018 A catalytic and metal free sulfoxidation of O-2-(2-propylthiol)benzyl (OPTB) glycosides to O-2-(2-propylsulfinyl)benzyl (OPSB) glycosides has been developed by introducing NOBF4 as catalyst, oxygen as terminal oxidant and TBAB as additive. Tetrabutylammonium bromide 222-226 immunoglobulin kappa variable 1D-39 Homo sapiens 91-94 30094991-1 2018 Two unprecedented examples of cluster organic frameworks (TBA)3Cu[V6O13(L)2]2 4DEF (2) (TBA)Ag[V6O13(L)2] solvent (3) (TBA = tetrabutylammonium, H3L = tris(hydroxymethyl)-4-picoline, DEF = N, N"-diethylformamide) based on Lindqvist-type polyoxometalate (POM) secondary building units (SBUs) have been constructed successfully. Tetrabutylammonium bromide 125-143 UTP25 small subunit processome component Homo sapiens 79-82 29567366-3 2018 The resulting dinuclear anionic complexes can be separated on a reversed-phase C18 column using tetrabutylammonium chloride as an ion-pairing reagent. Tetrabutylammonium bromide 96-123 Bardet-Biedl syndrome 9 Homo sapiens 79-82 32089129-5 2020 The maximum monolayer adsorption capacity of the fly ash-tetrabutylammonium bromide was found to be 863 mg g-1 and 670 mg g-1 for chromium and Rhodamine B, respectively. Tetrabutylammonium bromide 57-83 goliath Drosophila melanogaster 107-125 31292406-1 2019 We herein report a rare case of a 41-year-old woman with painless thyroiditis who was positive for TSH receptor-blocking (TBAbs) and receptor-stimulating autoantibodies (TSAbs) in the thyrotoxic phase. Tetrabutylammonium bromide 122-127 thyroid stimulating hormone receptor Homo sapiens 99-111 30303391-1 2018 The first asymmetric nucleophilic fluorination at the sp3-tertiary carbon center has been developed using inexpensive tetrabutylammonium fluoride (TBAF) without any metal/catalyst for the synthesis of 3-fluoro-3-substituted oxindoles with excellent enantioselectivity (ee up to >99%). Tetrabutylammonium bromide 118-145 Sp3 transcription factor Homo sapiens 54-57 30303391-1 2018 The first asymmetric nucleophilic fluorination at the sp3-tertiary carbon center has been developed using inexpensive tetrabutylammonium fluoride (TBAF) without any metal/catalyst for the synthesis of 3-fluoro-3-substituted oxindoles with excellent enantioselectivity (ee up to >99%). Tetrabutylammonium bromide 147-151 Sp3 transcription factor Homo sapiens 54-57 29135954-10 2017 The alkali metal cations, tetrabutylammonium (TBA+), Mg2+ and Ag+, interact with the C-2 carbonyl oxygen of the isatin anion. Tetrabutylammonium bromide 26-44 complement C2 Homo sapiens 85-88 29064238-4 2017 Two irreversible reductions are observed for (TpYPP)CoII and butano(TpYPP)CoII in CH2Cl2 containing 0.1 M tetra-n-butylammonium perchlorate; the first leads to the formation of a highly reactive cobalt(I) porphyrin, which can then rapidly react with a solvent to give a CoIIICH2Cl as the product. Tetrabutylammonium bromide 106-139 mitochondrially encoded cytochrome c oxidase II Homo sapiens 52-56 29064238-4 2017 Two irreversible reductions are observed for (TpYPP)CoII and butano(TpYPP)CoII in CH2Cl2 containing 0.1 M tetra-n-butylammonium perchlorate; the first leads to the formation of a highly reactive cobalt(I) porphyrin, which can then rapidly react with a solvent to give a CoIIICH2Cl as the product. Tetrabutylammonium bromide 106-139 mitochondrially encoded cytochrome c oxidase II Homo sapiens 74-78 28182857-2 2017 The unexpected reaction of one of these 1,4-oxazepanes in the presence of TBAF provided a 4-oxa-1-azabicyclo[4.1.0]heptane core. Tetrabutylammonium bromide 74-78 OXA1L mitochondrial inner membrane protein Homo sapiens 92-97 31457282-4 2017 Urea derivative L 1 facilitates the reaction of TBAF with glass to form tetrabutylammonium hexafluorosilicate, which on further interaction with L 1 forms cocrystal 2L 1 (TBA)2SiF6. Tetrabutylammonium bromide 48-52 L1 cell adhesion molecule Homo sapiens 16-19 31457282-4 2017 Urea derivative L 1 facilitates the reaction of TBAF with glass to form tetrabutylammonium hexafluorosilicate, which on further interaction with L 1 forms cocrystal 2L 1 (TBA)2SiF6. Tetrabutylammonium bromide 48-52 L1 cell adhesion molecule Homo sapiens 145-148 28439882-1 2017 The prevalence and clinical relevance of thyroid stimulating hormone (TSH) receptor (TSHR) blocking antibodies (TBAb) in patients with autoimmune thyroid disease (AITD) was investigated. Tetrabutylammonium bromide 112-116 thyroid stimulating hormone receptor Homo sapiens 85-89 26067891-4 2015 For surfactants with comparatively short alkyl chains (C6 and C10), the alkyl chains prefer to interact with tetrabutylammonium, the countercation of hexamolybdate. Tetrabutylammonium bromide 109-127 complement C6 Homo sapiens 55-65 28005345-2 2017 The ligand reacted with Fe(ClO4)2 6H2O or Fe(ClO4)3 6H2O in the presence of tetrabutylammonium perchlorate, and Et3N under air and provided a mu2 oxo-bridged dinuclear iron complex (1). Tetrabutylammonium bromide 76-106 adaptor related protein complex 1 subunit mu 2 Homo sapiens 142-145 25313472-3 2015 EXPERIMENTS: Previous research has established the conditions required for full exfoliation of HCN in aqueous solutions of tetrabutylammonium hydroxide (TBAOH), denoted as TBACN. Tetrabutylammonium bromide 123-151 metastasis associated lung adenocarcinoma transcript 1 Homo sapiens 95-98 25313472-3 2015 EXPERIMENTS: Previous research has established the conditions required for full exfoliation of HCN in aqueous solutions of tetrabutylammonium hydroxide (TBAOH), denoted as TBACN. Tetrabutylammonium bromide 153-158 metastasis associated lung adenocarcinoma transcript 1 Homo sapiens 95-98 24507930-4 2014 Each compound can undergo two metal-centered one-electron reductions leading to formation of Co(II) and Co(I) derivatives in CH2Cl2 or pyridine containing 0.1 M tetra-n-butylammonium perchlorate (TBAP). Tetrabutylammonium bromide 161-194 mitochondrially encoded cytochrome c oxidase II Homo sapiens 93-99 24507930-4 2014 Each compound can undergo two metal-centered one-electron reductions leading to formation of Co(II) and Co(I) derivatives in CH2Cl2 or pyridine containing 0.1 M tetra-n-butylammonium perchlorate (TBAP). Tetrabutylammonium bromide 161-194 mitochondrially encoded cytochrome c oxidase I Homo sapiens 104-109 24507930-4 2014 Each compound can undergo two metal-centered one-electron reductions leading to formation of Co(II) and Co(I) derivatives in CH2Cl2 or pyridine containing 0.1 M tetra-n-butylammonium perchlorate (TBAP). Tetrabutylammonium bromide 196-200 mitochondrially encoded cytochrome c oxidase II Homo sapiens 93-99 24507930-4 2014 Each compound can undergo two metal-centered one-electron reductions leading to formation of Co(II) and Co(I) derivatives in CH2Cl2 or pyridine containing 0.1 M tetra-n-butylammonium perchlorate (TBAP). Tetrabutylammonium bromide 196-200 mitochondrially encoded cytochrome c oxidase I Homo sapiens 104-109 24507930-9 2014 Thin-layer UV-visible spectroelectrochemical measurements in CH2Cl2, 0.1 M TBAP demonstrate the occurrence of an equilibrium between a Co(III) pi-anion radical and a Co(II) derivative with an uncharged macrocycle after the first controlled potential reduction of the nitro-substituted corroles. Tetrabutylammonium bromide 75-79 mitochondrially encoded cytochrome c oxidase III Homo sapiens 135-142 24507930-9 2014 Thin-layer UV-visible spectroelectrochemical measurements in CH2Cl2, 0.1 M TBAP demonstrate the occurrence of an equilibrium between a Co(III) pi-anion radical and a Co(II) derivative with an uncharged macrocycle after the first controlled potential reduction of the nitro-substituted corroles. Tetrabutylammonium bromide 75-79 mitochondrially encoded cytochrome c oxidase II Homo sapiens 166-172